NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AIFF yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital through equity sales and agreements | A supporting condition in FIREFLY NEUROSCIENCE INC's published investment case. The stated target is Maintain stable capital access without dilutive equity sales. | Under Pressure | Further termination of material agreements or heavy dilution | Material agreement terminated; $1.0M dilutive placement failed June 2026 8-K reports termination of the May 2026 securities purchase agreement for up to $1M. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established compounder: it is still loss-making and carries high risk. The multi-year view is on watch, as recent financial performance remains well below its industry cohort but has not freshly broken.
The valuation model indicates a sizable premium versus peers, while its confidence is low. The pricing signal is labeled justified, but the expectations gap is negative, suggesting limited support from the model for current expectations; the evidence does not specify exactly what growth the market assumes.
Near term, revenue has risen from $43,000 in 2025-Q1 to $514,000 in 2026-Q2, and the operating loss narrowed from $2,656,000 in 2025-Q3 to $1,974,000 in 2026-Q2. Losses remain significant, the risk label recently rose to high, and the CFO transition adds management uncertainty; private placements also show that capital raising remains part of the plan.
Over the next one to three years, the thesis hinges on whether strategic agreements can sustain revenue growth and whether operating losses keep narrowing. Near-term, Federal Reserve rate cuts or stabilization among major technology companies could support the sector, while GDP growth falling below 2% would be a headwind; the evidence gives no specific company-level forecast.
AIFF shows early progress in revenue growth and cost control, but persistent losses, high risk, and management changes keep the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 6 of last 6 quarters. Revenue grew from $43,000 in 2025-Q1 to $514,000 in 2026-Q2, showing a strong upward trajectory. Management's focus on strategic agreements aligns with this consistent revenue growth, indicating delivery on this priority.
Operating income improvement through cost management | It improved operating income by $491K in the same period. | Intact | operating loss worsens beyond -$2,501,000 after 2026-Q1 | Operating income: $-1.974M FY2026-Q2; GAAP. Published target: Operating loss better than -$2,010,000 in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 10, 2026-1,974,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Operating income loss improved from -$2,656,000 in 2025-Q3 to -$1,974,000 in 2026-Q2, indicating progress in cost management. The trajectory shows delivering improvement but operating losses remain significant. Delivery assessment Oct 31, 2026 |
Revenue growth through strategic agreements | A primary condition in FIREFLY NEUROSCIENCE INC's published investment case. The stated target is >= $485,000 revenue in 2026-Q1. | Intact | revenue falls below $412,000 in any quarter after 2026-Q1 | Revenue: $514,000 FY2026-Q2; GAAP. Published target: >= $485,000 revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 10, 2026514,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Revenue grew from $43,000 in 2025-Q1 to $514,000 in 2026-Q2, showing a strong upward trajectory. Management's focus on strategic agreements aligns with this consistent revenue growth, indicating delivery on this priority. Delivery assessment Oct 31, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.